Live Breaking News & Updates on Clinical biomarkers

Dxcover launches troika of trials to evaluate efficacy of cancer test

Dxcover Ltd. initiated three pivotal trials to measure the efficacy of its liquid biopsy platform for early detection of brain, colorectal and lung cancers. The company hopes the trials will provide the evidence needed to gain regulatory approval and begin commercial operations of its diagnostic technology in Europe and the U.S.

Dxcover-ltd , Bioworld-medtech , Brain-cancer , Colorectal-cancer , Dxcover-ltd , Lung-cancer , Clinical , Oncology , Diagnostics , Us- , Europe

Acurx's ibezapolstat posts positive phase II data but stock slips

Acurx Pharmaceuticals Inc. continues to post positive data for its lead candidate ibezapolstat but that didn’t stop the stock from tumbling. The antibiotic outperformed vancomycin in a phase IIb study treating Clostridioides difficile infection (CDI). Vancomycin is a standard of care in the indication. Ibezapolstat eradicated fecal CDI at day 3 in 15 of 16 patients compared to vancomycin, which eradicated fecal CDI in 10 of 14 patients.

Acurx-pharmaceuticals-inc , Acurx-pharmaceuticals , Acurx-pharmaceuticals-inc , Ibezapolstat , Wvancomycin , Clostridioides-difficile-infection , Ccdi , Bioworld , Clinical , Infection , Require-registration

Lirentelimab out on failed phase II data; Allakos restructures

Allakos Inc. terminated all development of its lead drug, anti-Siglec-8 antibody lirentelimab (AK-002), and is cutting its workforce in half, following phase II failures for atopic dermatitis and chronic spontaneous urticaria. The San Carlos, Calif.-based company will now focus on phase I trials for anti-Siglec-6 antibody AK-006 as part of a restructuring that stretches the runway into mid-2026. Shares (NASDAQ:ALLK) sank by 60.2%, down $1.80, to close at $1.19 on Jan. 16.

Allakos-inc , Nasdaq , San-carlos , Allakos-inc , Lirentelimab , Ak-002 , Atopic-dermatitis , Chronic-spontaneous-urticaria , Restructuring , Ak-006 , Bioworld

Transcripts for FOXNEWS Jesse Watters Primetime 20240604 06:51:00

most participants taken most participants taken before guard also haou. less muscle weakness, and you have been off guard treatment scheduleed is designed just for you in a clinical. y of i the most common side effects included and respiratory tract infectionsnf and headache. this guard may increase the risk of infection. the risk of infection. tell your doctor ailabl if you haveon. a history of infections or symptoms of an infection, this guard can cause allergic reactions available as guard for i.v infusion and also as vive guard. hi true low for subcutaneous hi true low for subcutaneous injection additionalal effects for vive guard are true though they include injection site reactions to talk to your neurologist about vive guard. why you shouldn t do that and what and you that i mean connecting to skilled professionals to get all your home projects done well so you can focus on the important stuff. i mean see millions of ratings and reviews so you can feel comfort in it means comparing quotes or booking at an upfront price so you can choose the best price for you because we want everyone to get

Guard , Participants , Headache , Clinical , Side-effects , Treatment-scheduleed , Muscle-weakness , Respiratory-tract-infectionsnf , Sthaou , Infection , Risk , Infections

The transfer that adds an element of anger to the League of Ireland title race

Nature of Pat Hoban’s exit from Dundalk provides a new dimension to Derry City’s challenge.

Tallaght , County-south-dublin , Ireland , Dundalk , Louth , Kortrijk , Region-flamande , Belgium , Cork-city , Cork , Tuam , Galway

N4 Pharma reports progress in Nuvec clinical research

Pharmaceutical delivery system developer N4 Pharma reported significant progress in its research efforts to enhance viral vector performance using Nuvec on Monday.

Nigel-theobald , University-of-brunel , Nanogenic-glaucoma , Pharma , Reports , Progress , Nuvec , Clinical , Research , Category-all , Category-market-report , Category-company-news

Destiny Pharma reports progress on clinical assets

Clinical-stage biotechnology company Destiny Pharma said in a year-end update on Thursday that its primary focus remained on realising the full potential of its XF-73 Nasal asset.

Chris-tovey , Sebela-pharmaceuticals , Destiny-pharma , Destiny , Pharma , Reports , Progress , Clinical , Assets , Category-all , Category-market-report , Category-company-news

Clinical psychologist Dr Phillipa Pehi sets out on her fourth hīkoi of Aotearoa

By Kelvin McDonald of Whakaata Maori How many whānau can say they have walked the length of Aotearoa at least once in their lifetime, let alone four times?.

Canada , Cape-reinga , New-zealand-general- , New-zealand , Auckland , Te-araroa , Rakiura , Tai-tokerau , Zena-nicholls , Hannah-irakau-pehi , Kelvin-mcdonald , Facebook

Medicinal cannabis company trialling substitute for sleep and pain medication in aged care facilities

A Christchurch -based medicinal marijuana company is leading New Zealand’s first clinical trial testing medicinal cannabis as a substitute for pain and sleep.

New-zealand , North-island , New-zealand-general- , Waikato , Morrinsville , Matamata , Aldo-miccio , Rocco-pienaar , Aether-pacific-pharmaceuticals , Pacific-pharmaceuticals , Medical-kiwi , Kingswood-healthcare